Blueprint Medicines Corporation Stock Forecast NASDAQ:BPMC

Price Target and Analyst Ratings

Most Recent Rating

On July 30, 2021 "Morgan Stanley" gave "$101.00 - $96.00" rating for BPMC. The price target was set to $85.90+1.4%.

Last 30 Days

Historical Ratings

Date	Rating	Action	Authority	Current Price	Target Price
2021-07-30	$101.00 - $96.00	Target Lowered by	Morgan Stanley	$87.87	$85.90+1.4%
2021-06-17	Outperform	Target Raised by	SVB Leerink	$83.53	$127.00 → $137.00
2021-06-17	Outperform	Target Raised by	Robert W. Baird	$83.53	$119.00 → $123.00
2021-06-17	Outperform	Target Lowered by	Wedbush	$83.53	$136.00 → $130.00
2021-05-06	Equal Weight	Target Lowered by	Morgan Stanley	$93.18	$105.00 → $101.00
2021-04-30	Equal Weight	Target Lowered by	Morgan Stanley	$96.32	$105.00 → $101.00
2021-04-19	Outperform	Target Raised by	Wedbush	$93.81	$119.00 → $136.00
2021-04-13	Outperform	Target Raised by	Wedbush	$93.08	$119.00 → $136.00
2021-04-13	Outperform	Reiterated by	Wedbush	$93.08	$119.00 → $136.00
2021-03-30	Neutral	Initiated by	Credit Suisse Group	$93.27
2021-02-25	Equal Weight	Target Lowered by	Morgan Stanley	$96.09	$112.00 → $105.00
2021-02-25	Equal Weight	Target Raised by	Barclays	$96.09	$90.00 → $95.00
2021-02-18	Buy	Reiterated by	HC Wainwright	$96.74
2021-02-18	Equal Weight	Target Raised by	Barclays	$96.74	$90.00 → $95.00
2021-01-12	Positive - Outperform	Target Raised by	SVB Leerink	$107.22	$121.00 → $127.00
2021-01-12	Outperform	Target Raised by	SVB Leerink	$107.22	$121.00 → $127.00
2020-12-18	Outperform	Target Raised by	JMP Securities	$123.64	$118.00 → $152.00
2020-12-14	Outperform	Target Raised by	BMO Capital Markets	$117.31	$113.00 → $132.00
2020-12-02	Hold	Initiated by	Stifel Nicolaus	$105.61
2020-11-02	Buy - Hold	Downgraded by	Jefferies Financial Group	$98.47	$90.00 → $96.00
2020-11-02	Buy	Target Raised by	HC Wainwright	$98.47	$110.00 → $135.00
2020-10-30	Overweight - Equal Weight	Downgraded by	Morgan Stanley	$102.28	$112.00
2020-10-30		Target Raised by	Wedbush	$102.28	$102.00 → $115.00
2020-10-29	Neutral	Target Raised by	Piper Sandler	$106.84	$77.00 → $81.00
2020-10-16	Positive - Strong-Buy	Target Raised by	Raymond James	$102.33	$106.00 → $122.00
2020-10-13	Overweight	Target Raised by	Morgan Stanley	$100.22	$92.00 → $100.00
2020-09-23	Equal Weight	Target Raised by	Barclays	$89.64	$77.00 → $90.00
2020-09-23	Outperform	Target Raised by	BMO Capital Markets	$89.64	$105.00 → $113.00
2020-09-23	Outperform	Target Raised by	SVB Leerink	$89.64	$107.00 → $121.00
2020-09-22	Buy	Reiterated by	Raymond James	$87.27
2020-09-02	Buy	Reiterated by	Raymond James	$77.06
2020-07-31	Buy	Reiterated by	HC Wainwright	$73.18
2020-07-27	Outperform	Target Raised by	SVB Leerink	$75.76	$106.00 → $107.00
2020-07-27	Outperform	Target Raised by	SVB Leerink	$75.76	$106.00 → $107.00
2020-06-08	Positive - Buy	Target Raised by	Deutsche Bank	$74.30	$70.00 → $85.00
2020-06-08	Outperform	Target Raised by	BMO Capital Markets	$74.30	$75.00 → $111.00
2020-05-07	Buy	Reiterated by	HC Wainwright	$60.18	$66.00
2020-04-30	Overweight	Target Lowered by	Morgan Stanley	$58.83	$103.00 → $88.00
2020-04-30	Buy	Target Lowered by	Canaccord Genuity	$58.83	$115.00 → $100.00
2020-04-29	Outperform	Target Lowered by	BMO Capital Markets	$60.13	$89.00 → $75.00
2020-04-29	Outperform	Target Lowered by	SVB Leerink	$60.13	$125.00 → $105.00
2020-04-29	Buy	Target Lowered by	HC Wainwright	$60.13	$100.00 → $66.00
2020-04-29	Market Outperform	Target Lowered by	JMP Securities	$60.13	$107.00 → $103.00

BPMC Stock Trend

The stockhas broken the wide and falling short-term trend up. Firstly a slower falling rate is indicated, but this may very well be an early signal of a trend shift. On the reaction, there will be support on the roof of the current trend broken, which is $86.21, a level that may pose a second chance to hit a runner. According to fan-theory $95.02 will be the next possible trend-top level and thereby pose a resistance level that may not be broken at the first attempt.

WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.

Data

Date	Bottom	Mid	Top
2021-08-03	$77.21	$81.61	$86.02
2021-08-04	$77.02	$81.42	$85.83
2021-08-05	$76.82	$81.23	$85.63
2021-08-06	$76.63	$81.04	$85.44
2021-08-09	$76.44	$80.84	$85.25
2021-08-10	$76.25	$80.65	$85.06
2021-08-11	$76.06	$80.46	$84.86
2021-08-12	$75.86	$80.27	$84.67
2021-08-13	$75.67	$80.08	$84.48
2021-08-16	$75.48	$79.88	$84.29
2021-08-17	$75.29	$79.69	$84.10
2021-08-18	$75.10	$79.50	$83.90
2021-08-19	$74.90	$79.31	$83.71
2021-08-20	$74.71	$79.12	$83.52
2021-08-23	$74.52	$78.92	$83.33
2021-08-24	$74.33	$78.73	$83.14
2021-08-25	$74.14	$78.54	$82.94
2021-08-26	$73.94	$78.35	$82.75
2021-08-27	$73.75	$78.16	$82.56
2021-08-30	$73.56	$77.96	$82.37
2021-08-31	$73.37	$77.77	$82.18
2021-09-01	$73.17	$77.58	$81.98
2021-09-02	$72.98	$77.39	$81.79
2021-09-03	$72.79	$77.19	$81.60
2021-09-07	$72.60	$77.00	$81.41
2021-09-08	$72.41	$76.81	$81.21
2021-09-09	$72.21	$76.62	$81.02
2021-09-10	$72.02	$76.43	$80.83
2021-09-13	$71.83	$76.23	$80.64
2021-09-14	$71.64	$76.04	$80.45

About Blueprint Medicines Corporation

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Its lead drug candidates include BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patie... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!